Teresa E Parodi, PA
Physician Assistant · Santa Cruz
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Dominican Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Teresa E Parodi’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$107,508
Medicare paid this office $107,508 for 436 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 203 | $65,838 | $128 |
| Return visit (30+ min) | 285 | $37,675 | $86 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 149 | $3,246 | $11 |
Who their Medicare patients are
436 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 14% · Women 60% · Also on Medicaid 14% · Health risk score 1.97. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 66% · Cancer 54% · Chronic kidney disease 23% · Diabetes 21% · Coronary heart disease 21% · Depression 19% · Atrial fibrillation 18% · Heart failure 14% · COPD 14% · Dementia 5% · Stroke 5%.
The office billed $454,381, Medicare allowed $139,294 and paid $107,508; for 1,872 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 436 | 1,872 | 76 | 1.97 | $454,381 | $107,508 |
| 2023 | 526 | 2,152 | 76 | 1.82 | $513,909 | $134,901 |
| 2022 | 369 | 1,565 | 75 | 1.84 | $382,370 | $102,555 |
| 2021 | 312 | 924 | 75 | 2.01 | $285,275 | $78,576 |
| 2020 | 322 | 1,000 | 75 | 2.05 | $279,358 | $70,969 |
| 2019 | 351 | 4,657 | 75 | 1.86 | $517,043 | $149,771 |
| 2018 | 367 | 1,759 | 74 | 2.03 | $356,032 | $81,049 |
| 2017 | 331 | 1,400 | 75 | 2.00 | $341,787 | $79,321 |
| 2016 | 224 | 444 | 74 | 2.22 | $132,391 | $30,613 |
| 2015 | 157 | 300 | 73 | 1.84 | $79,054 | $18,764 |
| 2014 | 85 | 146 | 74 | 1.74 | $25,615 | $6,369 |
| 2013 | 98 | 118 | 71 | 1.42 | $29,137 | $7,263 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 234 | $80,230 | $131 |
| Return visit (30+ min) | 338 | $44,656 | $93 |
2022: 4 services
| Long return visit (40+ min) | 173 | $57,218 | $134 |
| Return visit (30+ min) | 222 | $33,893 | $90 |
| New patient visit (45+ min) | 18 | $2,223 | $123 |
| Short return visit (20+ min) | 18 | $1,245 | $69 |
2021: 3 services
| Return visit (30+ min) | 292 | $66,520 | $93 |
| Long return visit (40+ min) | 50 | $9,010 | $137 |
| Short return visit (20+ min) | 11 | $832 | $69 |
2020: 4 services
| Return visit (30+ min) | 305 | $64,831 | $80 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $2,595 | $81 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $674 | $56 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 12 | $148 | $11 |
2019: 2 services
| Return visit (30+ min) | 333 | $75,765 | $80 |
| Short return visit (20+ min) | 19 | $1,050 | $52 |
2018: 3 services
| Return visit (30+ min) | 357 | $78,550 | $74 |
| Short return visit (20+ min) | 13 | $683 | $53 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 41 | $470 | $9 |
2017: 3 services
| Return visit (30+ min) | 324 | $77,291 | $73 |
| Short return visit (20+ min) | 16 | $724 | $43 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 13 | $157 | $10 |
2016: 2 services
| Return visit (30+ min) | 186 | $26,450 | $73 |
| Short return visit (20+ min) | 46 | $2,314 | $45 |
2015: 3 services
| Return visit (30+ min) | 95 | $11,161 | $74 |
| Short return visit (20+ min) | 79 | $5,031 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,229 | $95 |
2014: 2 services
| Short return visit (20+ min) | 51 | $3,191 | $51 |
| Return visit (30+ min) | 35 | $2,613 | $73 |
2013: 3 services
| Short return visit (20+ min) | 65 | $3,589 | $47 |
| New patient visit (15+ min) | 17 | $830 | $49 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 12 | $127 | $11 |
Drugs they prescribed that Part D paid
$3,282,353
Pharmacies billed $3,282,353 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (22 of 829) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
599 generic and 230 brand-name prescriptions · $3,282,353 in drug cost · 38 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Imbruvica | 57 | $837,756 | $14,697 |
| Revlimid | 41 | $810,640 | $19,772 |
| Ibrance | 20 | $301,178 | $15,059 |
| Lenalidomide | 20 | $296,907 | $14,845 |
| Jakafi | 12 | $211,198 | $17,600 |
See all 20 drugs
| Imbruvica | 57 | $837,756 | $14,697 |
| Revlimid | 41 | $810,640 | $19,772 |
| Ibrance | 20 | $301,178 | $15,059 |
| Lenalidomide | 20 | $296,907 | $14,845 |
| Jakafi | 12 | $211,198 | $17,600 |
| Venclexta | 11 | $78,194 | $7,109 |
| Xarelto | 20 | $29,691 | $1,485 |
| Eliquis | 14 | $18,308 | $1,308 |
| Anastrozole | 139 | $2,800 | $20 |
| Abiraterone Acetate | 19 | $2,503 | $132 |
| Exemestane | 25 | $2,199 | $88 |
| Hydroxyurea | 26 | $1,200 | $46 |
| Tamoxifen Citrate | 36 | $1,036 | $29 |
| Letrozole | 17 | $647 | $38 |
| Acyclovir | 14 | $429 | $31 |
| Prednisone | 47 | $267 | $6 |
| Potassium Chloride | 13 | $218 | $17 |
| Hydrocodone-Acetaminophen | 17 | $179 | $11 |
| Lorazepam | 36 | $133 | $4 |
| Ondansetron | 17 | $68 | $4 |
Year by year
| 2024 | 829 | 214 | 3% (22) | 28% | $3,282,353 |
| 2023 | 918 | 242 | 3% (30) | None | $4,466,327 |
| 2022 | 1,191 | 298 | 6% (71) | None | $5,786,539 |
| 2021 | 1,208 | 303 | 7% (80) | None | $4,128,489 |
| 2020 | 1,081 | 275 | 11% (113) | 20% | $2,470,330 |
| 2019 | 925 | 248 | 6% (55) | 20% | $1,466,677 |
| 2018 | 778 | 227 | 11% (83) | 8% | $409,992 |
| 2017 | 955 | 230 | 9% (85) | 11% | $225,297 |
| 2016 | 1,009 | 241 | 8% (77) | 12% | $252,874 |
| 2015 | 649 | 179 | 10% (62) | 9% | $167,167 |
| 2014 | 543 | 157 | 10% (53) | 7% | $118,074 |
| 2013 | 803 | 294 | 6% (49) | 24% | $57,477 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Imbruvica | 82 | $1,213,741 | $14,802 |
| Revlimid | 48 | $988,597 | $20,596 |
| Ibrance | 36 | $585,430 | $16,262 |
| Lenalidomide | 41 | $540,477 | $13,182 |
| Tagrisso | 12 | $231,787 | $19,316 |
| Xtandi | 14 | $117,773 | $8,412 |
| Eliquis | 18 | $25,209 | $1,401 |
| Xarelto | 21 | $23,181 | $1,104 |
| Exemestane | 19 | $7,250 | $382 |
| Anastrozole | 158 | $3,712 | $23 |
| Raloxifene | 11 | $2,241 | $204 |
| Tamoxifen Citrate | 33 | $1,784 | $54 |
| Letrozole | 34 | $1,332 | $39 |
| Hydroxyurea | 22 | $841 | $38 |
| Acyclovir | 18 | $754 | $42 |
| Dexamethasone | 15 | $693 | $46 |
| Hydrocodone-Acetaminophen | 23 | $377 | $16 |
| Lorazepam | 30 | $254 | $8 |
| Prochlorperazine Maleate | 21 | $249 | $12 |
| Potassium Chloride | 15 | $208 | $14 |
| Prednisone | 22 | $169 | $8 |
| Sulfamethoxazole-Trimethoprim | 16 | $169 | $11 |
| Cephalexin | 14 | $134 | $10 |
2022: 25 drugs
| Revlimid | 133 | $2,646,006 | $19,895 |
| Imbruvica | 69 | $935,003 | $13,551 |
| Ibrance | 34 | $502,140 | $14,769 |
| Pomalyst | 12 | $258,162 | $21,513 |
| Xtandi | 23 | $215,256 | $9,359 |
| Lenalidomide | 17 | $195,472 | $11,498 |
| Jakafi | 11 | $189,084 | $17,189 |
| Venclexta | 11 | $79,104 | $7,191 |
| Abiraterone Acetate | 26 | $38,367 | $1,476 |
| Exemestane | 44 | $19,463 | $442 |
| Xarelto | 13 | $15,315 | $1,178 |
| Anastrozole | 233 | $6,733 | $29 |
| Raloxifene | 16 | $2,798 | $175 |
| Tamoxifen Citrate | 46 | $2,566 | $56 |
| Hydroxyurea | 47 | $2,191 | $47 |
| Hydrocodone-Acetaminophen | 56 | $1,261 | $23 |
| Letrozole | 38 | $1,219 | $32 |
| Dexamethasone | 13 | $341 | $26 |
| Bicalutamide | 11 | $275 | $25 |
| Prochlorperazine Maleate | 24 | $274 | $11 |
| Prednisone | 38 | $268 | $7 |
| Acyclovir | 13 | $268 | $21 |
| Lorazepam | 39 | $183 | $5 |
| Ondansetron | 11 | $104 | $9 |
| Cephalexin | 11 | $72 | $7 |
2021: 26 drugs
| Revlimid | 96 | $1,608,263 | $16,753 |
| Imbruvica | 69 | $960,015 | $13,913 |
| Pomalyst | 23 | $445,812 | $19,383 |
| Ibrance | 23 | $325,487 | $14,152 |
| Venclexta | 14 | $189,622 | $13,544 |
| Xtandi | 16 | $97,092 | $6,068 |
| Abiraterone Acetate | 60 | $64,593 | $1,077 |
| Imatinib Mesylate | 25 | $17,238 | $690 |
| Exemestane | 30 | $11,233 | $374 |
| Anastrozole | 183 | $5,667 | $31 |
| Xarelto | 11 | $5,275 | $480 |
| Hydroxyurea | 65 | $3,098 | $48 |
| Enoxaparin | 12 | $2,978 | $248 |
| Raloxifene | 16 | $2,864 | $179 |
| Tamoxifen Citrate | 63 | $2,642 | $42 |
| Letrozole | 33 | $1,366 | $41 |
| Hydrocodone-Acetaminophen | 56 | $1,099 | $20 |
| Dexamethasone | 21 | $497 | $24 |
| Prednisone | 52 | $438 | $8 |
| Gabapentin | 23 | $372 | $16 |
| Ondansetron | 19 | $333 | $18 |
| Acyclovir | 11 | $321 | $29 |
| Bicalutamide | 15 | $243 | $16 |
| Prochlorperazine Maleate | 17 | $190 | $11 |
| Lorazepam | 41 | $152 | $4 |
| Furosemide | 21 | $125 | $6 |
2020: 26 drugs
| Revlimid | 40 | $682,425 | $17,061 |
| Imbruvica | 48 | $609,859 | $12,705 |
| Xtandi | 32 | $240,132 | $7,504 |
| Abiraterone Acetate | 23 | $50,265 | $2,185 |
| Imatinib Mesylate | 11 | $9,981 | $907 |
| Exemestane | 21 | $9,441 | $450 |
| Enoxaparin | 12 | $7,264 | $605 |
| Anastrozole | 178 | $4,191 | $24 |
| Tamoxifen Citrate | 57 | $3,312 | $58 |
| Hydroxyurea | 40 | $1,511 | $38 |
| Hydrocodone-Acetaminophen | 77 | $1,022 | $13 |
| Acyclovir | 23 | $773 | $34 |
| Ondansetron Odt | 14 | $533 | $38 |
| Letrozole | 14 | $477 | $34 |
| Oxycodone-Acetaminophen | 14 | $442 | $32 |
| Ondansetron | 21 | $351 | $17 |
| Morphine Sulfate Er | 13 | $341 | $26 |
| Lorazepam | 68 | $325 | $5 |
| Pantoprazole | 11 | $308 | $28 |
| Dexamethasone | 14 | $301 | $22 |
| Gabapentin | 23 | $295 | $13 |
| Diphenoxylate-Atropine | 14 | $243 | $17 |
| Prednisone | 24 | $187 | $8 |
| Nystatin | 15 | $166 | $11 |
| Prochlorperazine Maleate | 13 | $156 | $12 |
| Omeprazole | 12 | $128 | $11 |
2019: 25 drugs
| Imbruvica | 43 | $489,852 | $11,392 |
| Xtandi | 26 | $254,076 | $9,772 |
| Zytiga | 23 | $231,284 | $10,056 |
| Abiraterone Acetate | 25 | $69,644 | $2,786 |
| Enoxaparin | 15 | $7,805 | $520 |
| Exemestane | 20 | $6,243 | $312 |
| Anastrozole | 124 | $3,677 | $30 |
| Tamoxifen Citrate | 48 | $2,343 | $49 |
| Hydroxyurea | 33 | $1,326 | $40 |
| Dexamethasone | 20 | $842 | $42 |
| Hydrocodone-Acetaminophen | 37 | $577 | $16 |
| Gabapentin | 12 | $419 | $35 |
| Lorazepam | 77 | $387 | $5 |
| Acyclovir | 14 | $282 | $20 |
| Ondansetron | 18 | $277 | $15 |
| Warfarin | 11 | $220 | $20 |
| Omeprazole | 16 | $213 | $13 |
| Letrozole | 13 | $201 | $15 |
| Sulfamethoxazole-Trimethoprim | 15 | $199 | $13 |
| Prednisone | 26 | $183 | $7 |
| Diphenoxylate-Atropine | 11 | $182 | $17 |
| Cephalexin | 13 | $118 | $9 |
| Prochlorperazine Maleate | 14 | $98 | $7 |
| Zolpidem | 15 | $83 | $6 |
| Triamcinolone Acetonide | 14 | $70 | $5 |
2018: 22 drugs
| Imatinib Mesylate | 13 | $151,556 | $11,658 |
| Zytiga | 11 | $108,961 | $9,906 |
| Exemestane | 15 | $5,822 | $388 |
| Enoxaparin | 13 | $5,228 | $402 |
| Anastrozole | 109 | $1,738 | $16 |
| Tamoxifen Citrate | 34 | $1,446 | $43 |
| Hydrocodone-Acetaminophen | 52 | $957 | $18 |
| Hydroxyurea | 14 | $784 | $56 |
| Ventolin Hfa | 12 | $661 | $55 |
| Lorazepam | 92 | $448 | $5 |
| Dexamethasone | 20 | $444 | $22 |
| Lidocaine-Prilocaine | 17 | $440 | $26 |
| Prednisone | 34 | $307 | $9 |
| Prochlorperazine Maleate | 19 | $149 | $8 |
| Warfarin | 11 | $148 | $13 |
| Azithromycin | 14 | $142 | $10 |
| Zolpidem | 21 | $132 | $6 |
| Paroxetine | 11 | $101 | $9 |
| Ondansetron Odt | 16 | $99 | $6 |
| Lidocaine Hcl Viscous | 11 | $83 | $8 |
| Omeprazole | 11 | $72 | $7 |
| Gabapentin | 13 | $63 | $5 |
2017: 19 drugs
| Anastrozole | 107 | $1,733 | $16 |
| Tamoxifen Citrate | 48 | $1,259 | $26 |
| Hydroxyurea | 26 | $1,258 | $48 |
| Morphine Sulfate Er | 12 | $703 | $59 |
| Lorazepam | 146 | $685 | $5 |
| Hydrocodone-Acetaminophen | 48 | $647 | $13 |
| Lidocaine-Prilocaine | 23 | $578 | $25 |
| Zolpidem | 30 | $294 | $10 |
| Ondansetron Odt | 20 | $285 | $14 |
| Dexamethasone | 20 | $231 | $12 |
| Ondansetron | 21 | $198 | $9 |
| Levofloxacin | 11 | $177 | $16 |
| Venlafaxine Hcl Er | 22 | $176 | $8 |
| Prochlorperazine Maleate | 28 | $148 | $5 |
| Gabapentin | 18 | $117 | $6 |
| Omeprazole | 23 | $89 | $4 |
| Ciprofloxacin | 11 | $68 | $6 |
| Paroxetine | 11 | $56 | $5 |
| Levothyroxine | 11 | $28 | $3 |
2016: 17 drugs
| Enoxaparin | 12 | $7,865 | $655 |
| Xarelto | 17 | $6,211 | $365 |
| Anastrozole | 85 | $1,474 | $17 |
| Lidocaine-Prilocaine | 45 | $1,264 | $28 |
| Lorazepam | 183 | $1,006 | $5 |
| Hydrocodone-Acetaminophen | 41 | $947 | $23 |
| Tamoxifen Citrate | 28 | $740 | $26 |
| Hydroxyurea | 27 | $661 | $24 |
| Ondansetron | 48 | $605 | $13 |
| Dexamethasone | 41 | $503 | $12 |
| Prochlorperazine Maleate | 54 | $383 | $7 |
| Acyclovir | 13 | $315 | $24 |
| Letrozole | 22 | $313 | $14 |
| Ondansetron Odt | 23 | $270 | $12 |
| Zolpidem | 15 | $189 | $13 |
| Prednisone | 19 | $186 | $10 |
| Omeprazole | 29 | $148 | $5 |
2015: 17 drugs
| Enoxaparin | 11 | $7,916 | $720 |
| Tamoxifen Citrate | 45 | $1,069 | $24 |
| Hydrocodone-Acetaminophen | 37 | $1,042 | $28 |
| Anastrozole | 45 | $975 | $22 |
| Hydroxyurea | 14 | $586 | $42 |
| Diphenoxylate-Atropine | 13 | $580 | $45 |
| Lidocaine-Prilocaine | 17 | $569 | $33 |
| Ondansetron | 37 | $425 | $11 |
| Lorazepam | 81 | $411 | $5 |
| Prednisone | 27 | $324 | $12 |
| Prochlorperazine Maleate | 44 | $260 | $6 |
| Zolpidem | 18 | $217 | $12 |
| Gabapentin | 16 | $198 | $12 |
| Letrozole | 21 | $169 | $8 |
| Dexamethasone | 22 | $163 | $7 |
| Omeprazole | 22 | $162 | $7 |
| Sulfamethoxazole-Trimethoprim | 12 | $66 | $6 |
2014: 12 drugs
| Zytiga | 11 | $41,594 | $3,781 |
| Anastrozole | 88 | $2,745 | $31 |
| Tamoxifen Citrate | 47 | $1,233 | $26 |
| Ondansetron | 29 | $584 | $20 |
| Hydrocodone-Acetaminophen | 30 | $566 | $19 |
| Lorazepam | 62 | $348 | $6 |
| Gabapentin | 15 | $319 | $21 |
| Prednisone | 28 | $249 | $9 |
| Letrozole | 13 | $238 | $18 |
| Zolpidem | 21 | $130 | $6 |
| Prochlorperazine Maleate | 22 | $128 | $6 |
| Dexamethasone | 11 | $124 | $11 |
2013: 15 drugs
| Moviprep | 141 | $9,889 | $70 |
| Anastrozole | 78 | $2,313 | $30 |
| Ondansetron | 77 | $2,152 | $28 |
| Exemestane | 11 | $2,119 | $193 |
| Omeprazole | 34 | $737 | $22 |
| Prochlorperazine Maleate | 68 | $486 | $7 |
| Hydrocodone-Acetaminophen | 24 | $431 | $18 |
| Lorazepam | 76 | $421 | $6 |
| Lidocaine-Prilocaine | 15 | $413 | $28 |
| Dexamethasone | 25 | $263 | $11 |
| Letrozole | 12 | $260 | $22 |
| Tamoxifen Citrate | 11 | $234 | $21 |
| Prednisone | 28 | $184 | $7 |
| Zolpidem | 23 | $120 | $5 |
| Allopurinol | 17 | $90 | $5 |
Money from drug and device companies
$24 in 2025
| 2025 | 1 | 1 | None | $24 |
| 2024 | 5 | 5 | None | $123 |
| 2023 | 1 | 1 | None | $26 |
| 2022 | 1 | 1 | None | $32 |
| 2021 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| SpringWorks Therapeutics | None | $24 | 1 payment
|
See the published payment
| SpringWorks Therapeutics | Meals · 2025-01-09 | None | $24 |
See earlier years (2024, 2023, 2022, 2021)
2024: $123
| Amgen | Evenity | $40 | 1 payment
|
| GlaxoSmithKline | Jemperli | $33 | 1 payment
|
| Array Biopharma | Xalkori | $20 | 1 payment
|
| Celgene | Reblozyl | $17 | 1 payment
|
| SpringWorks Therapeutics | Ogsiveo | $14 | 1 payment
|
2023: $26
| Janssen Biotech | None | $26 | 1 payment
|
2022: $32
| Pfizer | Ibrance | $32 | 1 payment
|
2021: $12
| Acrotech Biopharma | Beleodaq | $12 | 1 payment
|
Professional record
- NPI
- 1891736732
- Licence
- CA PA15285
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 2850 Commercial Xing, Santa Cruz, CA, 95065
- NPI first listed
- 2006-06-10
- NPI last updated
- 2013-06-20
This is when the NPI record was last certified, not a medical board exam.